Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN   US75886F1075

SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

Regeneron: Sanofi Plans to Increase Stake to Over $500 Million of Stock

02/11/2013 | 10:44am US/Eastern
   By Melodie Warner 
 

Regeneron Pharmaceuticals Inc. (>> Regeneron Pharmaceuticals Inc) said Sanofi S.A. (SNY, SAN.FR) notified the biopharmaceutical company of its intent to boost its investment in the company and push its ownership of voting securities to more than $500 million.

Sanofi currently holds about 17% of Regeneron's shares outstanding, according to FactSet Research.

Regeneron said a December 2007 investor agreement bonds the French drug maker to certain standstill provisions, including an agreement not to acquire more than 30% of Regeneron's Class A stock and common stock outstanding.

Regeneron said these standstill provisions are in effect until the fifth anniversary of the expiration of a license and collaboration agreement between the companies.

Sanofi and Regeneron have worked together on experimental cancer drug Zaltrap, among other things.

Shares of Regeneron rose 5.6% to $175.13 in recent trading and have climbed 24% in the past three months.

Write to Melodie Warner at melodie.warner@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Regeneron Pharmaceuticals Inc
Latest news on REGENERON PHARMACEUTICALS
1d ago REGENERON PHARMACEUTICALS : Assigned Patent
2d ago REGENERON PHARMACEUTICALS : Ranked Number One Biopharmaceutical Employer by Scie..
2d ago REGENERON PHARMACEUTICALS : Reports on Vaccines from Regeneron Pharmaceuticals I..
2d ago REGENERON PHARMACEUTICALS : EYLEA® aflibercept Injection Demonstrates Significan..
3d ago SANOFI : and Regeneron Announce Start of Phase 3 Study of Dupilumab in Patients ..
3d ago REGENERON PHARMACEUTICALS : Earns Top Spot as Employer in the Global Biopharmace..
4d ago REGENERON PHARMACEUTICALS : and Sanofi Announce Start of Phase 3 Study of Dupilu..
5d ago REGENERON PHARMACEUTICALS : FDA OKs Eylea (aflibercept) Injection
7d ago REGENERON PHARMACEUTICALS : S&P 500 Analyst Moves: REGN
7d agoDJAmgen Files Patent Infringement Suit Over Cholesterol Drug
Advertisement
Chart
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF